About
RNA-modifying protein inhibitors
Areas of Focus
Categories
Small Molecule PharmaceuticalBoston & New England
Team (13)
Clinical Trials (2)
View allTotal Trials
2
As Lead Sponsor
2
As Collaborator
0
Total Enrollment
165
By Phase
PHASE1: 2
By Status
RECRUITING: 2
Clinical Trials Pipeline2 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT06799065Lead Sponsor
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
PHASE1Recruiting
65 participants
Started: Mar 21, 2025 · Completed: Aug 30, 2027
NCT06625515Lead Sponsor
First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
PHASE1Recruiting
100 participants
Started: Oct 11, 2024 · Completed: Feb 28, 2027
Locations (1)
Headquarters
Lexington, MA, United States
Map
Loading map...